This study is the first to demonstrate that sodium butyrate treatment alleviates MP-induced hypertension and kidney disease in young rats, likely through reduced oxidative stress, altered gut microbiota, increased butyric acid, and enhanced renal GPR43 expression. The gene discussed is FFAR2; the disease is hypertensive disorder.